The high-profile COVID-19 antiviral drug Remdesivir is not getting recommended for hospitalized COVID-19 patients by an advisory body of the UN health agency. On Thursday, they said that there is no sufficient proof that it will improve or upgrade the patient’s survival or lower the possibility of putting patients on ventilators.
A Guideline Development Group (GDG) panel of WHO, including international specialists recommended in the British Medical Association, published a weekly peer-reviewed medical journal – BMJ. It provided “living guidelines” to control COVID-19 and help doctors so that they can consult with patients and make better decisions.
In a press release, WHO said about the findings that those living guidelines were useful at first as new and updated facts allowed researchers to renovate previously evaluated and peer-reviewed evidence. Although Remdesivir’s role in clinical practice has remained unsettled, it drew worldwide attention in treating many COVID-19 cases and it was massively used for hospitalized patients.
Comparing the outcomes of many other coronavirus’s antiviral drugs, WHO recommended some new evidence based on data from four global randomized trials of COVID-19 patients of more than 7,000.
The WHO GDG specialists including four people who were previously attacked by coronavirus reviewed the evidence and came to the point that the antiviral drug Remdesivir has no assurance that it will improve or upgrade the patient’s clinical improvement or lower the possibility of putting patients on ventilators or reduce the death rate.
Still, the GDG is supporting the trial of Remdesivir on patients to decide if more significant proof can be acquired, mainly for certain groups of patients. A feature article from the press release of WHO, linked to BMJ’s panel report stated that until and unless Gilead, the manufacturer of Remdesivir provides full clinical study reports, the complete story behind the antivirus will not be understood.
Journalist Jeremy Hsu, writer of the feature also stated that other treatments like corticosteroid, dexamethasone are reducing the death rate within some severely-ill COVID-19 patients which are impacting Remdesivir’s cost-effectiveness.